19.12
price down icon2.99%   -0.59
after-market アフターアワーズ: 19.12
loading
前日終値:
$19.71
開ける:
$19.76
24時間の取引高:
1.67M
Relative Volume:
0.90
時価総額:
$3.29B
収益:
$1.10B
当期純損益:
$375.65M
株価収益率:
8.7056
EPS:
2.1963
ネットキャッシュフロー:
$113.59M
1週間 パフォーマンス:
-3.34%
1か月 パフォーマンス:
-30.57%
6か月 パフォーマンス:
-10.02%
1年 パフォーマンス:
-7.27%
1日の値動き範囲:
Value
$18.87
$19.76
1週間の範囲:
Value
$18.39
$19.88
52週間の値動き範囲:
Value
$18.39
$30.96

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
名前
Acadia Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
858-558-2871
Name
住所
12830 EL CAMINO REAL, SAN DIEGO
Name
職員
798
Name
Twitter
@acadiapharma
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
ACAD's Discussions on Twitter

Compare ACAD vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ACAD icon
ACAD
Acadia Pharmaceuticals Inc
19.12 3.29B 1.10B 375.65M 113.59M 2.1963
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-13 ダウングレード UBS Buy → Neutral
2026-03-25 アップグレード BofA Securities Neutral → Buy
2026-02-24 開始されました Wolfe Research Outperform
2026-02-23 アップグレード Mizuho Neutral → Outperform
2025-10-21 開始されました Citigroup Buy
2025-05-21 アップグレード Deutsche Bank Hold → Buy
2025-02-11 開始されました Deutsche Bank Hold
2025-01-03 ダウングレード Guggenheim Buy → Neutral
2024-10-10 再開されました Raymond James Mkt Perform
2024-08-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-06-27 開始されました BMO Capital Markets Outperform
2024-03-12 ダウングレード Mizuho Buy → Neutral
2024-03-12 繰り返されました Needham Buy
2024-01-30 開始されました Robert W. Baird Outperform
2024-01-24 アップグレード Needham Hold → Buy
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-12-14 ダウングレード Deutsche Bank Buy → Hold
2023-12-13 開始されました Citigroup Buy
2023-12-12 開始されました Deutsche Bank Buy
2023-11-06 アップグレード Mizuho Neutral → Buy
2023-10-17 開始されました UBS Buy
2023-10-10 アップグレード JP Morgan Neutral → Overweight
2023-01-03 アップグレード Guggenheim Neutral → Buy
2022-11-04 ダウングレード Goldman Neutral → Sell
2022-11-01 開始されました Loop Capital Hold
2022-08-08 ダウングレード Citigroup Buy → Neutral
2022-08-05 ダウングレード Citigroup Buy → Neutral
2022-06-21 ダウングレード Jefferies Buy → Underperform
2022-06-16 アップグレード Jefferies Hold → Buy
2022-03-16 アップグレード Canaccord Genuity Hold → Buy
2022-02-09 アップグレード H.C. Wainwright Neutral → Buy
2022-01-05 アップグレード Citigroup Neutral → Buy
2021-12-21 ダウングレード Guggenheim Buy → Neutral
2021-11-01 アップグレード Guggenheim Neutral → Buy
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-06-10 開始されました Berenberg Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-06 ダウングレード Canaccord Genuity Buy → Hold
2021-04-06 ダウングレード Goldman Buy → Neutral
2021-04-06 ダウングレード Jefferies Buy → Hold
2021-04-06 ダウングレード Mizuho Buy → Neutral
2021-04-05 ダウングレード Raymond James Outperform → Mkt Perform
2021-03-10 ダウングレード BofA Securities Buy → Neutral
2021-03-09 ダウングレード Citigroup Buy → Neutral
2021-03-09 ダウングレード Guggenheim Buy → Neutral
2021-03-09 繰り返されました H.C. Wainwright Buy
2021-03-09 ダウングレード Raymond James Strong Buy → Outperform
2021-03-09 ダウングレード Stifel Buy → Hold
2020-12-16 開始されました Mizuho Buy
2020-11-16 アップグレード Raymond James Outperform → Strong Buy
2020-08-25 開始されました Raymond James Outperform
2020-08-20 開始されました Morgan Stanley Overweight
2020-07-07 アップグレード Stifel Hold → Buy
2020-04-16 開始されました Jefferies Buy
2020-03-31 アップグレード Goldman Neutral → Buy
2020-03-06 開始されました Citigroup Buy
2019-12-16 開始されました Guggenheim Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-01 開始されました RBC Capital Mkts Outperform
2019-09-13 アップグレード SVB Leerink Mkt Perform → Outperform
2019-09-10 アップグレード Canaccord Genuity Hold → Buy
2019-07-23 繰り返されました Needham Buy
2018-12-10 開始されました Canaccord Genuity Hold
2018-09-21 アップグレード Piper Jaffray Neutral → Overweight
2018-08-09 繰り返されました Stifel Hold
2018-08-07 開始されました Stifel Hold
2018-08-06 ダウングレード Piper Jaffray Overweight → Neutral
2017-10-06 再開されました Goldman Neutral
すべてを表示

Acadia Pharmaceuticals Inc (ACAD) 最新ニュース

pulisher
Oct 15, 2026

Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire

Oct 15, 2026
pulisher
Oct 15, 2026

UBS cuts target for ACADIA Pharmaceuticals stock to USD 23.00 - ad-hoc-news.de

Oct 15, 2026
pulisher
Oct 15, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance

Oct 15, 2026
pulisher
Oct 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire

Oct 15, 2026
pulisher
Oct 15, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada

Oct 15, 2026
pulisher
Oct 14, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK

Oct 14, 2026
pulisher
Oct 13, 2026

Law firm probes ACADIA investors' claims after trial misses key endpoint, stock drops sharply. - Pluang

Oct 13, 2026
pulisher
Oct 13, 2026

Acadia Pharmaceuticals stock hits 52-week low at 19.01 USD - Investing.com

Oct 13, 2026
pulisher
Oct 13, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target - Yahoo Finance

Oct 13, 2026
pulisher
Oct 09, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 08, 2026

RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating - Yahoo Finance

Oct 08, 2026
pulisher
Oct 07, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance

Oct 07, 2026
pulisher
Oct 06, 2026

RBC keeps Outperform on ACADIA Pharmaceuticals stock at USD 37 - AD HOC NEWS

Oct 06, 2026
pulisher
Oct 06, 2026

RBC reiterates Outperform on ACADIA Pharmaceuticals stock - AD HOC NEWS

Oct 06, 2026
pulisher
Oct 05, 2026

Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Yahoo Finance

Oct 05, 2026
pulisher
Oct 05, 2026

Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook - GuruFocus

Oct 05, 2026
pulisher
Oct 05, 2026

RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments - Investing.com

Oct 05, 2026
pulisher
Oct 05, 2026

Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent L - GuruFocus

Oct 05, 2026
pulisher
Oct 04, 2026

ACADIA Pharmaceuticals Inc. (0A4W.IL) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 04, 2026
pulisher
Oct 03, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Oct 03, 2026
pulisher
Oct 02, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia

Oct 02, 2026
pulisher
Oct 01, 2026

Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com

Oct 01, 2026
pulisher
Oct 01, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire

Oct 01, 2026
pulisher
Sep 30, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance

Sep 30, 2026
pulisher
Sep 29, 2026

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research

Sep 29, 2026
pulisher
Sep 29, 2026

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance

Sep 29, 2026
pulisher
Sep 29, 2026

Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ

Sep 29, 2026
pulisher
Sep 29, 2026

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - biospace.com

Sep 29, 2026
pulisher
Sep 28, 2026

Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus

Sep 28, 2026
pulisher
Sep 28, 2026

Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance

Sep 28, 2026
pulisher
Sep 28, 2026

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance

Sep 28, 2026
pulisher
Sep 27, 2026

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance

Sep 27, 2026
pulisher
Sep 26, 2026

Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st

Sep 26, 2026
pulisher
Sep 25, 2026

Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus

Sep 25, 2026
pulisher
Sep 25, 2026

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha

Sep 25, 2026
pulisher
Sep 25, 2026

Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance

Sep 25, 2026
pulisher
Sep 25, 2026

Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ

Sep 25, 2026
pulisher
Sep 24, 2026

Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily

Sep 24, 2026
pulisher
Sep 24, 2026

ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet

Sep 24, 2026
pulisher
Sep 24, 2026

Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com

Sep 24, 2026
pulisher
Sep 24, 2026

Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha

Sep 24, 2026
pulisher
Sep 24, 2026

Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - biospace.com

Sep 24, 2026
pulisher
Sep 24, 2026

Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha

Sep 24, 2026
pulisher
Sep 24, 2026

ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - Yahoo Finance

Sep 24, 2026

Acadia Pharmaceuticals Inc (ACAD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Acadia Pharmaceuticals Inc (ACAD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 06 '26
Sale
29.22
14,292
417,604
67,828
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 05 '26
Option Exercise
17.84
5,849
104,346
73,677
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 05 '26
Sale
29.00
5,849
169,638
67,828
Schneyer Mark C.
Officer
Aug 05 '26
Proposed Sale
27.15
5,849
158,800
0
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev
Jul 30 '26
Sale
26.13
16,558
432,663
18,994
Kihara James
Officer
Jun 26 '26
Proposed Sale
26.00
11,421
297,000
0
JAMES K KIHARA
Officer
May 26 '26
Proposed Sale
21.18
5,401
114,394
0
Kihara James
PRINCIPAL ACCOUNTING OFFICER
May 26 '26
Sale
21.18
5,401
114,393
24,509
Kihara James
PRINCIPAL ACCOUNTING OFFICER
May 04 '26
Sale
21.79
1,332
29,024
29,129
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
May 04 '26
Sale
21.79
3,506
76,396
66,145
$33.49
price down icon 2.45%
$25.17
price down icon 8.04%
$68.07
price down icon 4.11%
$32.85
price down icon 2.95%
$16.28
price down icon 5.90%
$18.48
price down icon 6.67%
大文字化:     |  ボリューム (24 時間):